Information updates

3 second EpiPen®s are now available

June 13, 2017:

EpiPen® and EpiPen®Jr adrenaline (epinephrine) autoinjectors with the 3 second label will start to enter pharmacies in Australia and New Zealand from 13 June 2017 onwards. 

The devices have not changed, just the instructions on the label, which now include:

  • Reduced injection time from 10 to 3 seconds – this is based on research confirming efficacy and delivery of adrenaline through the 3 second delivery.
  • Removal of the massage step after the injection – this has been found to reduce the risk of tissue irritation.

Whilst it is important that anyone who requires anaphylaxis training (including school and early childhood education/care staff) are aware of the changes, there is no need for immediate re-training on the 3 second EpiPen®.

EpiPen®s with a 10 second label can continue to be used and should not be replaced unless they have been used, are just about to expire or have expired.  

All EpiPen®s should now be held in place for 3 seconds, regardless of the instructions on the label.  However, if they are held for 10 seconds it will not affect the way that the adrenaline works. 

To access updated ASCIA Action Plans for Anaphylaxis, ASCIA anaphylaxis e-training courses, the 3 second EpiPen® training video and other resources go to www.allergy.org.au/anaphylaxis  

 

EpiPen

EpiPen 3 second 

Content updated 13 June 2017

Mod ASCIA Member
Donate to AIFA
go to NAS website
Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information.Verify here.